B
Brian J. P. Huntly
Researcher at University of Cambridge
Publications - 168
Citations - 21295
Brian J. P. Huntly is an academic researcher from University of Cambridge. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 54, co-authored 144 publications receiving 19135 citations. Previous affiliations of Brian J. P. Huntly include Cambridge University Hospitals NHS Foundation Trust & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
Brian J. P. Huntly,Hirokazu Shigematsu,Kenji Deguchi,Benjamin H. Lee,Shinichi Mizuno,Nicky Duclos,Rebecca Rowan,Sonia M Amaral,David P. Curley,Ifor R. Williams,Koichi Akashi,D. Gary Gilliland,D. Gary Gilliland +12 more
TL;DR: It is demonstrated that some, but not all, leukemia oncogenes can confer properties of leukemic stem cells to hematopoietic progenitors destined to undergo apoptotic cell death.
Journal ArticleDOI
Leukaemia stem cells and the evolution of cancer-stem-cell research
TL;DR: The leukaemia stem cell is likely to be the most crucial target in the treatment of leukaemias, and a thorough understanding of its biology — particularly of how the LSC differs from the HSC — might allow it to be selectively targeted, improving therapeutic outcome.
Journal ArticleDOI
Cancer stem cell definitions and terminology: the devil is in the details
Peter Valent,Dominique Bonnet,Ruggero De Maria,Tsvee Lapidot,Mhairi Copland,Junia V. Melo,Christine Chomienne,Fumihiko Ishikawa,Jan Jacob Schuringa,Giorgio Stassi,Brian J. P. Huntly,Harald Herrmann,Jean Soulier,Alexander Roesch,Gerrit Jan Schuurhuis,Stefan Wöhrer,Michel Arock,Johannes Zuber,Sabine Cerny-Reiterer,Hans Erik Johnsen,Michael Andreeff,Connie J. Eaves +21 more
TL;DR: More precise reporting of the parameters that are used to identify CSCs and to attribute responses to them is recommended as key to accelerating an understanding of their biology and developing more effective methods for their eradication in patients.
Journal ArticleDOI
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille N. Abboud,Ellin Berman,Adam D. Cohen,Jorge E. Cortes,Daniel J. DeAngelo,Michael W. Deininger,Steven M. Devine,Brian J. Druker,Amir T. Fathi,Elias Jabbour,Madan Jagasia,Hagop M. Kantarjian,Jean Khoury,Pierre Laneuville,Richard A. Larson,Jeffrey H. Lipton,Joseph O. Moore,Tariq I. Mughal,Susan O'Brien,Javier Pinilla-Ibarz,Alfonso Quintás-Cardama,Jerald P. Radich,Vishnu Reddy,Charles A. Schiffer,Neil P. Shah,Paul J. Shami,Richard T. Silver,David S. Snyder,Richard Stone,Moshe Talpaz,Ayalew Tefferi,Richard A. Van Etten,Meir Wetzler,Elisabetta Abruzzese,Jane F. Apperley,Massimo Breccia,Jenny Byrne,Francisco Cervantes,Ekaterina Chelysheva,Richard E. Clark,Hugues de Lavallade,Iryna Dyagil,Carlo Gambacorti-Passerini,John M. Goldman,Ibrahim C. Haznedaroglu,Henrik Hjorth-Hansen,Tessa L. Holyoake,Brian J. P. Huntly,Philipp le Coutre,Elza Lomaia,Francois-Xavier Mahon,David Marin-Costa,Giovanni Martinelli,Jiri Mayer,Dragana Milojkovic,Eduardo Olavarria,Kimmo Porkka,Johan Richter,Philippe Rousselot,Giuseppe Saglio,Güray Saydam,Jesper Stentoft,Anna G. Turkina,Paolo Vigneri,Andrey Zaritskey,Alvaro Aguayo,Manuel Ayala,Israel Bendit,Raquel Bengió,Carlos Best,Eduardo Bullorsky,Eduardo Cervera,Carmino DeSouza,Ernesto Fanilla,David Gómez-Almaguer,Nelson Hamerschlak,José A. López,Alicia Magarinos,Luis Meillon,Jorge Milone,Beatriz Moiraghi,Ricardo Pasquini,Carolina Pavlovsky,Guillermo J. Ruiz-Argüelles,Nelson Spector,Christopher Arthur,Peter Browett,Andrew Grigg,Jianda Hu,Xiao-Jun Huang,Timothy P. Hughes,Qian Jiang,Saengsuree Jootar,Dong-Wook Kim,Hemant Malhotra,Pankaj Malhotra,Itaru Matsumura,Junia V. Melo,Kazunori Ohnishi,Ryuzo Ohno,Tapan Saikia,Anthony P. Schwarer,Naoto Takahashi,Constantine S. Tam,Tetsuzo Tauchi,Kensuke Usuki,Jianxiang Wang,Fawzi Abdel-Rahman,Mahmoud Aljurf,Ali Bazarbachi,Dina Ben Yehuda,Naeem Chaudhri,Muheez A. Durosinmi,Hossam Kamel,Vernon J. Louw,Bassam Francis Matti,Arnon Nagler,Pia Raanani,Ziad Salem +118 more
TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Journal ArticleDOI
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Konstantinos Tzelepis,Hiroko Koike-Yusa,Etienne De Braekeleer,Yang Li,Emmanouil Metzakopian,Oliver M. Dovey,Annalisa Mupo,Vera V. Grinkevich,Meng Li,Milena Mazan,Malgorzata Gozdecka,Shuhei Ohnishi,Jonathan L. Cooper,Miten Patel,Thomas McKerrell,Bin Chen,Ana Domingues,Paolo Gallipoli,Sarah A. Teichmann,Hannes Ponstingl,Ultan McDermott,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Brian J. P. Huntly,Francesco Iorio,Cristina Pina,George S. Vassiliou,George S. Vassiliou,Kosuke Yusa +28 more
TL;DR: KAT2A inhibition demonstrated anti-AML activity by inducing myeloid differentiation and apoptosis, and suppressed the growth of primary human AMLs of diverse genotypes while sparing normal hemopoietic stem-progenitor cells.